The effect of chia seeds on non-alcoholic fatty liver disease

Evaluation of the effects of Chia seeds (Salvia hispanica) on nutritional status, metabolic factors, liver function, inflammatory hematologic and atherogenic indices in obese patients with non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100209003320N23

Enrollment

Registered

2024-01-30

Start date

2024-02-20

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: "Intervention group": patients in this group will receive chia seeds along with a weight loss diet, taking into account that 100 grams of chia seeds contain 486 calories (approximately

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Both genders Age range of 18 to 60 years body mass index= 30- 39.9 Kg/m2 Hepatic steatosis based on ultrasound findings (grade 1 and 2) willingness to participate in the study

Exclusion criteria

Exclusion criteria: Athletes pregnancy breastfeeding menopause Under infertility treatment taking birth control pills estrogen therapy Smoking history of alcohol consumption Taking medications including chemical or herbal medications for weight loss anti-hypertensive Fat-lowering drugs Sugar-lowering drugs any nutritional supplements from 3 months before the study Having cardiovascular diseases Liver dysfunction Kidney dysfunction Intestinal dysfunction Thyroid dysfunction Parathyroid dysfunction known autoimmune diseases polycystic ovary syndrome cancers Following a special diet in the last three months performing weight loss surgery in the last one year Taking Phenytoin medicine Taking amoxifene medicine Taking lithium medicine Performing or being a candidate for liver transplantation

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: Baseline and after 8 weeks. Method of measurement: ELISA method.;Hemoglobin A1C. Timepoint: Baseline and after 8 weeks. Method of measurement: chromatography.;Total cholesterol. Timepoint: Baseline and after 8 weeks. Method of measurement: Enzymatic method.;Triglyceride. Timepoint: Baseline and after 8 weeks. Method of measurement: Enzymatic method.;HDL cholesterol. Timepoint: Baseline and after 8 weeks. Method of measurement: Enzymatic-colorimetric method using spectrophotometer.;LDL cholesterol. Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the ?Friedelwald formula.;Insulin resistance indices (HOMA-IR, HOMA-B and QUICKI). Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the formula.;Body mass index(BMI). Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the formula.;Waist circumference. Timepoint: Baseline and after 8 weeks. Method of measurement: tape measure.;Waist to hips ratio (WHR). Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the formula.;Waist to Height ratio (WHTR). Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the formula.;Fat mass. Timepoint: Baseline and after 8 weeks. Method of measurement: Body analyzer.;Fat Free mass. Timepoint: Baseline and after 8 weeks. Method of measurement: Body analyzer.;Energy, macronutrients and micronutrients intake. Timepoint: Baseline and after 8 weeks. Method of measurement: 24- hr food recall questionnaire for 3 days and Nutritionist 4 software.;Physical activity level. Timepoint: Baseline and after 8 weeks. Method of measurement: IPAQ Questionnaire- short form.;Appetite status. Timepoint: Baseline and after 8 weeks. Method of measurement: Validated appetite questionnaire.;Body weight. Timepoint: Baseline and after 8 weeks. Method of measurement: Scale.;Fasting glucose. Timepoint: Baseline and after 8 weeks. Method of measurement: Enzymatic method.;Complete blood cell count (CBC). Ti	—

Measure

Time frame

Insulin. Timepoint: Baseline and after 8 weeks. Method of measurement: ELISA method.;Hemoglobin A1C. Timepoint: Baseline and after 8 weeks. Method of measurement: chromatography.;Total cholesterol. Timepoint: Baseline and after 8 weeks. Method of measurement: Enzymatic method.;Triglyceride. Timepoint: Baseline and after 8 weeks. Method of measurement: Enzymatic method.;HDL cholesterol. Timepoint: Baseline and after 8 weeks. Method of measurement: Enzymatic-colorimetric method using spectrophotometer.;LDL cholesterol. Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the ?Friedelwald formula.;Insulin resistance indices (HOMA-IR, HOMA-B and QUICKI). Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the formula.;Body mass index(BMI). Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the formula.;Waist circumference. Timepoint: Baseline and after 8 weeks. Method of measurement: tape measure.;Waist to hips ratio (WHR). Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the formula.;Waist to Height ratio (WHTR). Timepoint: Baseline and after 8 weeks. Method of measurement: Based on the formula.;Fat mass. Timepoint: Baseline and after 8 weeks. Method of measurement: Body analyzer.;Fat Free mass. Timepoint: Baseline and after 8 weeks. Method of measurement: Body analyzer.;Energy, macronutrients and micronutrients intake. Timepoint: Baseline and after 8 weeks. Method of measurement: 24- hr food recall questionnaire for 3 days and Nutritionist 4 software.;Physical activity level. Timepoint: Baseline and after 8 weeks. Method of measurement: IPAQ Questionnaire- short form.;Appetite status. Timepoint: Baseline and after 8 weeks. Method of measurement: Validated appetite questionnaire.;Body weight. Timepoint: Baseline and after 8 weeks. Method of measurement: Scale.;Fasting glucose. Timepoint: Baseline and after 8 weeks. Method of measurement: Enzymatic method.;Complete blood cell count (CBC). Ti

—

Secondary

Measure	Time frame
Fatty liver grade. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Ultrasonigraphy findings.;Alanine aminotransferase (ALT). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic method.;Aspartate aminotransferase (AST). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehrangiz Ebrahimi- Mameghani

Tabriz University of Medical Sciences

ebrahimimamagani@tbzmed.ac.ir+98 41 3335 7584

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026